ClinicalTrials.Veeva

Menu
A

Australian Alzheimer's Research Foundation | Clinical Trials Division

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Gantenerumab
LY3314814
Aducanumab
Lanabecestat
Lecanemab
Semaglutide
221AD301
221AD302
Simufilam
JNJ-63733657

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 20 total trials

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting
Early Alzheimer´s Disease
Drug: Placebo (semaglutide)
Drug: Semaglutide

The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration includ...

Enrolling
Alzheimer Disease
Mental Disorders
Drug: Placebo
Drug: Donanemab

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheime...

Active, not recruiting
Alzheimer Disease
Cognitive Dysfunction
Drug: JNJ-63733657
Drug: Placebo

The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Comp...

Enrolling
Preclinical Alzheimer's Disease
Drug: JNJ-64042056
Drug: Placebo

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiorit...

Active, not recruiting
Early Alzheimer's Disease
Drug: Placebo
Drug: Lecanemab

The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

A 52-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 52 we...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: Simufilam

Trial sponsors

Roche logo
AstraZeneca logo
Biogen logo
Eisai logo
A
C
Cognition Therapeutics logo
Janssen (J&J Innovative Medicine) logo
Janssen (J&J Innovative Medicine) logo
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems